CN102639487A - 治疗性芳基-酰氨基-芳基化合物以及它们的应用 - Google Patents
治疗性芳基-酰氨基-芳基化合物以及它们的应用 Download PDFInfo
- Publication number
- CN102639487A CN102639487A CN2010800493386A CN201080049338A CN102639487A CN 102639487 A CN102639487 A CN 102639487A CN 2010800493386 A CN2010800493386 A CN 2010800493386A CN 201080049338 A CN201080049338 A CN 201080049338A CN 102639487 A CN102639487 A CN 102639487A
- Authority
- CN
- China
- Prior art keywords
- independently
- compound according
- compound
- olr
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(C1=NC=C(*c2cc(I)c(*)c(*)c2)**1)=O Chemical compound *C(C1=NC=C(*c2cc(I)c(*)c(*)c2)**1)=O 0.000 description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N BrCc1ccccc1 Chemical compound BrCc1ccccc1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- ZAADKSCOCXBQRA-UHFFFAOYSA-N CC(C)Oc(c(Cl)cc(C(Nc1ccc(C(O)=O)c(C)c1)=O)c1)c1F Chemical compound CC(C)Oc(c(Cl)cc(C(Nc1ccc(C(O)=O)c(C)c1)=O)c1)c1F ZAADKSCOCXBQRA-UHFFFAOYSA-N 0.000 description 1
- LHOPUIURBJGDGM-UHFFFAOYSA-N CC(C)Oc(cc(cc1Cl)C(Nc2ccc(C(OC)=O)c(C)c2)=O)c1OC Chemical compound CC(C)Oc(cc(cc1Cl)C(Nc2ccc(C(OC)=O)c(C)c2)=O)c1OC LHOPUIURBJGDGM-UHFFFAOYSA-N 0.000 description 1
- NDAGZUHCIOWOMZ-UHFFFAOYSA-N CC(C)Oc(cc(cc1Cl)C(OC)=O)c1O Chemical compound CC(C)Oc(cc(cc1Cl)C(OC)=O)c1O NDAGZUHCIOWOMZ-UHFFFAOYSA-N 0.000 description 1
- PWMYGZVAXFXPNQ-UHFFFAOYSA-N CC(C)Oc1cc(C(O)=O)cc(Cl)c1OC Chemical compound CC(C)Oc1cc(C(O)=O)cc(Cl)c1OC PWMYGZVAXFXPNQ-UHFFFAOYSA-N 0.000 description 1
- HMHSEOXRZIQBJZ-UHFFFAOYSA-N CC(C)Oc1cc(CO)cc(OC(C)C)c1N Chemical compound CC(C)Oc1cc(CO)cc(OC(C)C)c1N HMHSEOXRZIQBJZ-UHFFFAOYSA-N 0.000 description 1
- BWRCMCJDXQPAGA-UHFFFAOYSA-N CC1[O](Cc2ccccc2)c(c(Cl)cc(C(OC)=O)c2)c2O1 Chemical compound CC1[O](Cc2ccccc2)c(c(Cl)cc(C(OC)=O)c2)c2O1 BWRCMCJDXQPAGA-UHFFFAOYSA-N 0.000 description 1
- QUPULIZWXWBCIV-UHFFFAOYSA-N CCOC(c(cc1)ccc1C(Nc(cc1Cl)cc(Cl)c1OCC)=O)=O Chemical compound CCOC(c(cc1)ccc1C(Nc(cc1Cl)cc(Cl)c1OCC)=O)=O QUPULIZWXWBCIV-UHFFFAOYSA-N 0.000 description 1
- JROYETJFPWLMSK-UHFFFAOYSA-N CCOc(c(C(F)(F)F)c1)c(C(F)(F)F)cc1NC(c(cc1)ccc1C(O)=O)=O Chemical compound CCOc(c(C(F)(F)F)c1)c(C(F)(F)F)cc1NC(c(cc1)ccc1C(O)=O)=O JROYETJFPWLMSK-UHFFFAOYSA-N 0.000 description 1
- RTTABJSYPXYQCK-UHFFFAOYSA-N CCOc(c(C(F)(F)F)c1)c(C(F)(F)F)cc1NC(c(cc1)ccc1C(OC)=O)=O Chemical compound CCOc(c(C(F)(F)F)c1)c(C(F)(F)F)cc1NC(c(cc1)ccc1C(OC)=O)=O RTTABJSYPXYQCK-UHFFFAOYSA-N 0.000 description 1
- JWBXFZUNIADZOI-UHFFFAOYSA-N CCOc(c(Cl)cc(C(Nc(cc1)ccc1C(N)=O)=O)c1)c1Cl Chemical compound CCOc(c(Cl)cc(C(Nc(cc1)ccc1C(N)=O)=O)c1)c1Cl JWBXFZUNIADZOI-UHFFFAOYSA-N 0.000 description 1
- RYOUVSCJCQTOSA-UHFFFAOYSA-N CCOc(c(Cl)cc(C(Nc1ccc(C(O)=O)c(C)c1)=O)c1)c1OC Chemical compound CCOc(c(Cl)cc(C(Nc1ccc(C(O)=O)c(C)c1)=O)c1)c1OC RYOUVSCJCQTOSA-UHFFFAOYSA-N 0.000 description 1
- SXYGOCJUQOJEPU-UHFFFAOYSA-N CCOc(c(Cl)cc(C(O)=O)c1)c1Cl Chemical compound CCOc(c(Cl)cc(C(O)=O)c1)c1Cl SXYGOCJUQOJEPU-UHFFFAOYSA-N 0.000 description 1
- JCYWFHRQFXSCCN-UHFFFAOYSA-N CCOc(c(Cl)cc(N)c1)c1Cl Chemical compound CCOc(c(Cl)cc(N)c1)c1Cl JCYWFHRQFXSCCN-UHFFFAOYSA-N 0.000 description 1
- JZKLPOCJBKWSSH-UHFFFAOYSA-N CCOc(cc1)c(C(F)(F)F)cc1C(Nc(cc1)ccc1C(O)=O)=O Chemical compound CCOc(cc1)c(C(F)(F)F)cc1C(Nc(cc1)ccc1C(O)=O)=O JZKLPOCJBKWSSH-UHFFFAOYSA-N 0.000 description 1
- XUOMUTYNGPAHPH-UHFFFAOYSA-N COC(c(cc1N)cc(OC)c1Cl)=O Chemical compound COC(c(cc1N)cc(OC)c1Cl)=O XUOMUTYNGPAHPH-UHFFFAOYSA-N 0.000 description 1
- ONHQYUZLIHPRMK-UHFFFAOYSA-N COC(c(cc1N=N)cc(OC)c1[O](C)=C)=O Chemical compound COC(c(cc1N=N)cc(OC)c1[O](C)=C)=O ONHQYUZLIHPRMK-UHFFFAOYSA-N 0.000 description 1
- QNYHMMOXMRPWTK-UHFFFAOYSA-N COC(c(cc1[N+]([O-])=O)cc(OC)c1Cl)=O Chemical compound COC(c(cc1[N+]([O-])=O)cc(OC)c1Cl)=O QNYHMMOXMRPWTK-UHFFFAOYSA-N 0.000 description 1
- QQDZRPJZLZWHJX-UHFFFAOYSA-N COc(cc(CO)cc1N=O)c1N Chemical compound COc(cc(CO)cc1N=O)c1N QQDZRPJZLZWHJX-UHFFFAOYSA-N 0.000 description 1
- PBFUETHMOZHHOH-UHFFFAOYSA-N C[O](c1cc(CO)ccc1N)=C Chemical compound C[O](c1cc(CO)ccc1N)=C PBFUETHMOZHHOH-UHFFFAOYSA-N 0.000 description 1
- NRTWXBXJSGGTTE-UHFFFAOYSA-N Cc1cc(N)ccc1C(OC)=O Chemical compound Cc1cc(N)ccc1C(OC)=O NRTWXBXJSGGTTE-UHFFFAOYSA-N 0.000 description 1
- QIKYZXDTTPVVAC-UHFFFAOYSA-N NC(c(cc1)ccc1N)=O Chemical compound NC(c(cc1)ccc1N)=O QIKYZXDTTPVVAC-UHFFFAOYSA-N 0.000 description 1
- KGEXISHTCZHGFT-UHFFFAOYSA-N Nc(cc1Cl)cc(Cl)c1O Chemical compound Nc(cc1Cl)cc(Cl)c1O KGEXISHTCZHGFT-UHFFFAOYSA-N 0.000 description 1
- RZYUIHNYUYKPOQ-UHFFFAOYSA-N Nc1cc(F)c(C(O)=O)c(F)c1 Chemical compound Nc1cc(F)c(C(O)=O)c(F)c1 RZYUIHNYUYKPOQ-UHFFFAOYSA-N 0.000 description 1
- HPYSNQHDVOVQIN-UHFFFAOYSA-N Nc1cc(F)c(C(OCc2ccccc2)=O)c(F)c1 Chemical compound Nc1cc(F)c(C(OCc2ccccc2)=O)c(F)c1 HPYSNQHDVOVQIN-UHFFFAOYSA-N 0.000 description 1
- AXKGIPZJYUNAIW-UHFFFAOYSA-N Nc1ccc(CO)cc1 Chemical compound Nc1ccc(CO)cc1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 1
- HAZWGQHRMHZOOS-UHFFFAOYSA-N OC(c(cc1)ccc1C(Nc(cc1Cl)cc(Cl)c1O)=O)=O Chemical compound OC(c(cc1)ccc1C(Nc(cc1Cl)cc(Cl)c1O)=O)=O HAZWGQHRMHZOOS-UHFFFAOYSA-N 0.000 description 1
- KNBNQKZMTPYPAS-UHFFFAOYSA-N OC(c(cc1)ccc1NC(c(cc1Cl)cc(OC2CCC2)c1OC1CCC1)=O)=O Chemical compound OC(c(cc1)ccc1NC(c(cc1Cl)cc(OC2CCC2)c1OC1CCC1)=O)=O KNBNQKZMTPYPAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0915196.0 | 2009-09-01 | ||
| GBGB0915196.0A GB0915196D0 (en) | 2009-09-01 | 2009-09-01 | Therapeutic compounds and their use |
| PCT/GB2010/001650 WO2011027106A1 (en) | 2009-09-01 | 2010-09-01 | Therapeutic aryl-am i do-aryl compounds and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102639487A true CN102639487A (zh) | 2012-08-15 |
Family
ID=41202973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800493386A Pending CN102639487A (zh) | 2009-09-01 | 2010-09-01 | 治疗性芳基-酰氨基-芳基化合物以及它们的应用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120149737A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2473479A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5778675B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102639487A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010291056B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012004173A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2771097C (cg-RX-API-DMAC7.html) |
| GB (1) | GB0915196D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL218137A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2012002481A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ598331A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2012108173A (cg-RX-API-DMAC7.html) |
| SG (1) | SG178480A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011027106A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201201287B (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071530A (zh) * | 2016-06-06 | 2018-12-21 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0915196D0 (en) | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
| EP2685972A4 (en) * | 2011-03-14 | 2014-08-13 | Io Therapeutics Inc | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH RAR ALPHA SELECTIVE AGONISTS |
| CN102727475B (zh) * | 2012-06-14 | 2014-05-07 | 合肥博太医药生物技术发展有限公司 | 视黄酸及其衍生物在制备防治老年痴呆药物中的应用 |
| CN107207488B (zh) * | 2014-12-17 | 2020-11-17 | 伦敦皇家学院 | 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物 |
| WO2016144976A1 (en) * | 2015-03-09 | 2016-09-15 | Kings College London | Combination therapy with rar alpha agonists for enhancing th1 response |
| WO2017066428A1 (en) | 2015-10-13 | 2017-04-20 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Brd4-kinase inhibitors as cancer therapeutics |
| US20190112272A1 (en) * | 2016-04-07 | 2019-04-18 | High Force Research Limited | Synthetic retinoids for use in rar mediated conditions |
| CA3124039A1 (en) * | 2018-12-19 | 2020-06-25 | King's College London | Immunotherapeutic methods and compositions |
| GB201900687D0 (en) | 2019-01-17 | 2019-03-06 | King S College London | Immunotherapeutic methods and compositions |
| CA3128032A1 (en) | 2019-01-29 | 2020-08-06 | The Johns Hopkins University | Small molecule neutral sphingomyelinase 2 (nsmase2) inhibitors |
| US12540121B2 (en) | 2019-06-28 | 2026-02-03 | Arizona Board Of Regents On Behalf Of Arizona State University | Compositions comprising a retinoid X receptor (RXR) agonist, a retinoic acid receptor (RAR) agonist, or a dual RXR/RAR agonist |
| JP2026500298A (ja) | 2022-12-15 | 2026-01-06 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤として有用である新規な二環式カルボキサミド化合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0515684A1 (en) * | 1990-02-14 | 1992-12-02 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of denatured ldl formation |
| CN1207727A (zh) * | 1995-11-22 | 1999-02-10 | 视觉药品公司 | 具有类视色素样生物活性的取代芳基或杂芳基酰胺类化合物 |
| KR100921173B1 (ko) * | 2007-11-14 | 2009-10-13 | (주)아모레퍼시픽 | 피부 내에서 히알루론산 생합성을 촉진시키는3,4,5-트리메톡시벤즈 아미드 유도체 화합물, 그 제조방법및 이를 함유하는 화장료 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2260118C2 (de) | 1972-12-08 | 1982-06-03 | Bayer Ag, 5090 Leverkusen | Penicilline sowie ihre Verwendung als Arzneimittel |
| EP0170105B1 (en) | 1984-07-07 | 1990-10-17 | Koichi Prof. Dr. Shudo | Benzoic acid derivatives |
| JPS61233678A (ja) | 1985-04-09 | 1986-10-17 | Maruko Seiyaku Kk | ベンジルピペラジン誘導体 |
| JPS62215581A (ja) | 1986-03-18 | 1987-09-22 | Koichi Shiyudo | フラボンカルボン酸誘導体 |
| US4808631A (en) | 1986-11-07 | 1989-02-28 | Hoffmann-La Roche Inc. | Aromatic acid derivatives |
| US4992468A (en) | 1989-07-26 | 1991-02-12 | Allergan, Inc. | Phenylethenyl compounds having retinoid-like activity |
| FR2663850B1 (fr) | 1990-07-02 | 1994-01-14 | Gird Galderma | Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol. |
| EP0619116A3 (en) | 1993-04-05 | 1994-11-23 | Hoechst Japan | Use of synthetic retinoids for osteopathy. |
| US5648385A (en) | 1994-01-03 | 1997-07-15 | Bristol-Myers Squibb Co. | Retinoid-like compounds |
| US5849735A (en) | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5559248A (en) | 1995-04-05 | 1996-09-24 | Bristol-Myers Squibb Co. | Retinoid-like heterocycles |
| AU693682B2 (en) | 1995-04-10 | 1998-07-02 | Taiho Pharmaceutical Co., Ltd. | Cancerous metastasis inhibitor |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| FR2739777B1 (fr) | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| WO2000001679A1 (en) | 1998-07-01 | 2000-01-13 | Takeda Chemical Industries, Ltd. | Retinoid-associated receptor regulators |
| US6245884B1 (en) | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
| EP1514867A3 (en) | 1998-10-22 | 2005-03-23 | NeuroSearch A/S | Substituted phenyl derivatives, their preparation and use |
| TW400614B (en) | 1998-11-06 | 2000-08-01 | United Microelectronics Corp | The manufacture method of Shallow Trench Isolation(STI) |
| CN1225468C (zh) | 2000-09-22 | 2005-11-02 | 全药工业株式会社 | 头孢烯化合物以及含有该化合物的esbl检测试剂 |
| AU2002231098A1 (en) | 2000-12-15 | 2002-06-24 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
| GB0103998D0 (en) | 2001-02-19 | 2001-04-04 | King S College London | Method |
| US7105566B2 (en) * | 2002-10-22 | 2006-09-12 | Allergan, Inc. | Methods of treatment during vascular procedures |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| BRPI1013392A2 (pt) | 2009-03-31 | 2016-03-29 | Renascience Co Ltd | inibidor do inibidor-1 do ativador do plasminogênio |
| GB0915196D0 (en) | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
| WO2012058378A1 (en) | 2010-10-29 | 2012-05-03 | Romark Laboratories L.C. | Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses |
-
2009
- 2009-09-01 GB GBGB0915196.0A patent/GB0915196D0/en not_active Ceased
-
2010
- 2010-09-01 RU RU2012108173/04A patent/RU2012108173A/ru not_active Application Discontinuation
- 2010-09-01 US US13/391,207 patent/US20120149737A1/en not_active Abandoned
- 2010-09-01 NZ NZ598331A patent/NZ598331A/xx not_active IP Right Cessation
- 2010-09-01 AU AU2010291056A patent/AU2010291056B2/en not_active Ceased
- 2010-09-01 CA CA2771097A patent/CA2771097C/en not_active Expired - Fee Related
- 2010-09-01 CN CN2010800493386A patent/CN102639487A/zh active Pending
- 2010-09-01 BR BR112012004173A patent/BR112012004173A2/pt not_active IP Right Cessation
- 2010-09-01 SG SG2012011193A patent/SG178480A1/en unknown
- 2010-09-01 MX MX2012002481A patent/MX2012002481A/es not_active Application Discontinuation
- 2010-09-01 EP EP10752907A patent/EP2473479A1/en not_active Withdrawn
- 2010-09-01 JP JP2012526118A patent/JP5778675B2/ja not_active Expired - Fee Related
- 2010-09-01 WO PCT/GB2010/001650 patent/WO2011027106A1/en not_active Ceased
-
2012
- 2012-02-16 IL IL218137A patent/IL218137A/en active IP Right Grant
- 2012-02-21 ZA ZA2012/01287A patent/ZA201201287B/en unknown
-
2015
- 2015-10-09 US US14/879,340 patent/US9447028B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0515684A1 (en) * | 1990-02-14 | 1992-12-02 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of denatured ldl formation |
| CN1207727A (zh) * | 1995-11-22 | 1999-02-10 | 视觉药品公司 | 具有类视色素样生物活性的取代芳基或杂芳基酰胺类化合物 |
| KR100921173B1 (ko) * | 2007-11-14 | 2009-10-13 | (주)아모레퍼시픽 | 피부 내에서 히알루론산 생합성을 촉진시키는3,4,5-트리메톡시벤즈 아미드 유도체 화합물, 그 제조방법및 이를 함유하는 화장료 조성물 |
Non-Patent Citations (2)
| Title |
|---|
| GARY M. COPPOLA ET AL.: "Perhydroquinolylbenzamides as Novel Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
| HOWARD TUCKER ET AL.: "Novel Inhibitors of Prolyl 4-Hydroxylase. 2. 5-Amide Substituted Pyridine-2-carboxylic Acids", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071530A (zh) * | 2016-06-06 | 2018-12-21 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
| CN109071530B (zh) * | 2016-06-06 | 2021-08-17 | 上海艾力斯医药科技股份有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0915196D0 (en) | 2009-10-07 |
| JP2013503819A (ja) | 2013-02-04 |
| MX2012002481A (es) | 2012-03-26 |
| IL218137A (en) | 2016-06-30 |
| US20160039747A1 (en) | 2016-02-11 |
| CA2771097C (en) | 2019-01-15 |
| NZ598331A (en) | 2013-10-25 |
| CA2771097A1 (en) | 2011-03-10 |
| AU2010291056B2 (en) | 2016-01-28 |
| EP2473479A1 (en) | 2012-07-11 |
| SG178480A1 (en) | 2012-04-27 |
| US20120149737A1 (en) | 2012-06-14 |
| RU2012108173A (ru) | 2013-10-10 |
| JP5778675B2 (ja) | 2015-09-16 |
| US9447028B2 (en) | 2016-09-20 |
| AU2010291056A1 (en) | 2012-03-15 |
| ZA201201287B (en) | 2013-05-29 |
| IL218137A0 (en) | 2012-06-28 |
| WO2011027106A1 (en) | 2011-03-10 |
| BR112012004173A2 (pt) | 2017-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5778675B2 (ja) | 治療性アリール−アミド−アリール化合物およびその使用 | |
| KR101302627B1 (ko) | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제 | |
| CN1867551B (zh) | 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物 | |
| US10214477B2 (en) | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | |
| RU2681211C2 (ru) | (гетеро)арилциклопропиламины в качестве ингибиторов lsd1 | |
| RU2280025C9 (ru) | Новые производные аминодикарбоновых кислот, обладающие фармацевтическими свойствами | |
| JP3953096B2 (ja) | サイクリックampホスホジエステラーゼおよびtnf阻害剤としての置換芳香族化合物 | |
| RU2493149C2 (ru) | Замещенные метилфенилкетоны, пригодные для использования в качестве ингибиторов pde4 | |
| JP2004525117A (ja) | 置換アミノジカルボン酸誘導体 | |
| IL184328A (en) | Substituted adamantyl-containing acetamides as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 and pharmaceutical compositions comprising the same | |
| TW201039814A (en) | Diacylethylenediamine compounds | |
| JP2021514963A (ja) | ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体 | |
| ES2907746T3 (es) | Compuestos de amida y uso de los mismos | |
| CA2566053A1 (en) | Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO1999027965A1 (en) | Antihyperlipemic agents | |
| AU2015367531A1 (en) | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists | |
| US9290444B2 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
| US8993632B2 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
| CN118414327A (zh) | 作为选择性phd1抑制剂的吡啶酰胺化合物、组合物和使用方法 | |
| KR20040028769A (ko) | 카텝신 억제제로서의 화합물 및 조성물 | |
| NZ622656B2 (en) | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120815 |